Open for inclusion

Everolimus and temozolmide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%

Cancer type: Gastric cancer

Phase: II

Principal Investigator: Sørbye Halfdan

Country: NO

Keywords: Norway, Bergen

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02248012?term=halfdan+Sorbye&rank=1